 Hey guys, how you doing? This is your boy Rich from Rich TV Live and you too can join the club at richpicksdaily.com where you can learn how to win and trade. Guys, how you doing? This is your boy Rich from Rich TV Live. Thank you guys for watching. We have a new pick for you. Put it on your radar, put it on your watch list. A-W-K-N in Canada. A-W-K-N-F in America. Awaken life sciences. Guys, we love revolutionary treatments for addiction. This is a company that is focusing on helping the world find revolutionary treatments for addiction. That's why you need to put them on your radar, put them on your watch list right here, right now exclusively with your boy Rich from Rich TV Live. Let's take a look. And Awaken Life Sciences Corp began trading in 2021 on the NeoExchange. This is what it looks like on the NeoExchange. You can see the last trade was at $3.10. And 135,000 traded in volume, a 77 million market cap. And that's mainly because when you look at the information on the company and you can scroll down, you can go to their website, AwakenLifeSciences.com. We'll just click on that. I'll take us right to the website, AwakenLifeSciences.com Revolutionary Treatments for Addiction. When you scroll down, you can find more details on the company. You can find all this information on the NeoExchange. Awaken Life Sciences Corp on the NeoExchange. And this is what the stock looks like. You can see that we've got a trend line here. It's really come up and had a lot of strength, been very, very strong. Let's take a look at this trend line. I'm going to remove all of this. And we're going to take a look here. I'm going to take a look. And we're going to look at the trend. So you can see here the trend has been extremely strong all the way up from $1.50 to where it trades today at $3.05. So this has been a strong, successful ride up in a market that isn't that rewarding. So that's a very good sign. When you see a stock do this well in a market, like I said, that really hasn't rewarded too many companies. This is one that has gone up over 100%. So definitely put AWKN on your watch list, put it on your radar. This is the symbol in America. AWKNF. And you can see a lot of the same in America. The trend line right up. Very, very bullish stock. AWKN in Canada. AWKNF in America. You can also see their news here. Awakened Life Sciences announces positive results. This came out just recently from phase two AB ketamine assisted therapy for treatment of alcohol use disorder trial. This came out on January 11th. So this news just came out. So be aware of the news, be aware of the share structure. We always talk about share structure. I think the share structure is something you need to be aware of. Look at the share structure, 24 million shares issuing outstanding. A really, really what we call a bingo share structure, everything you're looking for in the stock in that share structure. I'm gonna take a look at the corporate presentation. I also want you to be aware, the symbol in Canada on the new exchange, AWKN, in America on the OTCQB exchange, AWKNF, and in Frankfurt, Germany, nine, five, four. So triple listed in three of the biggest major trading exchanges. So who are they? We're a group of experts who are all leaders in our respective fields of psychiatry, psychology and neurochemistry who have joined together to make a real difference. We have driven relentlessly to make a genuine positive lasting impact on the lives of the individuals, their families and their communities who suffer with addiction and other mental health conditions. We're doing this by developing and delivering groundbreaking therapeutic approaches. The AWKN team. Can't wait to learn more about this company and the best way to learn about the company is to follow them on social media, do the due diligence, do the research and get to know the deal, okay? And AWKN Life Sciences is a biotechnology company researching, developing and delivering psychedelic therapeutics, medicines and therapies to treat addiction. AWKNs does this through the use of a variety of psychedelics, including ketamine. And we've been talking about psychedelics since it first launched. So this is the website AWKNLifeSciences.com. Once again, I always tell you guys, you gotta get to know these companies, right? So this is how I do it. I'll go to link it in, click on their link and I will follow them. I will literally follow them, follow all their news, get to know the company, right? You need to know who you're investing in. I must remind everyone that Rich TV Live is strictly for information and education purposes. Please do your due diligence, do your research before you invest in anything we talk about or discuss here on Rich TV Live. And saying that, we love to identify undervalued, underappreciated, underexposed opportunities. We are now following AWKN Life Sciences on Twitter and on LinkedIn and you can do that too. All of that information is right on their website. So I'm gonna show you guys some details. I'm gonna talk about a couple of things. I won't go through all of it but I wanna make sure we hit on some of the key focus points. Drugs and therapies used in combination. Addiction is one of the world's biggest unmet medical needs. Substance and behavioral addictions affect over 1.3 billion people worldwide yet all current treatments have high failure rates. AWKN is developing a better solution to treat addiction, psychedelic therapeutics, drugs and therapies used in combination. We're both a biotechnology company developing these proprietary therapeutics and an operator of clinics where we deliver them. Through clinical trials, our team has shown that this approach has the potential to be more effective than any addiction treatment currently available. We now aspire to become the market leader in effective addiction treatment meeting a vast global need that has failed by current approaches. So all this information is on the website. Please feel free to get awakened by doing the research, doing the due diligence and learning more about AWKN Life Sciences on their website on awakennlifesciences.com. Now I wanna continue here going through the presentation here. So very important to understand the company structure, focus on development and delivery, research, researching and developing ketamine, assisted psychotherapy for substance and behavioral addictions, MDMA, assisted psychotherapy for alcohol use disorder and next generation psychedelic drugs and therapies to treat addiction. Technology, enabling technologies to improve the effectiveness of psychedelics in treating addiction. Delivery, clinics, treat addiction and other mental health conditions, revenue generating in 2021 and partnerships that will be revenue generating in 2022. Scale our impact and reach through licensing partnerships and revenue generating into 2025 through therapeutic commercialization. Once marking, authorization has been secured for our therapies and drugs. We will commercialize them by scaling through traditional pharmaceutical channels. So be awakened with awaken. This is the management team. Anthony Tennyson is the co-founder and chief executive officer. Jonathan Held is the co-founder and chief financial officer. James Collins is the chief operating officer and you can see the rest of the team. Hopefully I'll get an opportunity to interview some of the members of this team. Like I said, this is what we do here at Rich TV Live while we're able to identify undervalued, underappreciated, under exposed companies because we put in the time to interview them, understand them, read their news, understand their fundamentals, watch the stock, look at the charts and really get to understand the team behind the deals. George Scorsese is the co-founder and chairman of the corporate board. And you can see here a long list of qualified members of this team and advisors. So obviously the focus here is on addiction, what and why? What is addiction? Why focus on addiction? And what is the market opportunity? Well, the market opportunity, the global substance addiction treatment industry was valued at US 17.5 billion per year in 2019 and is forecast to increase to US 31.5 billion per year by 2027. Now I must remind you that Rich TV Live is strictly for information education purposes. Do your due diligence, do your research before you invest anything we talk about or discuss here on Rich TV Live. So we try to break these deals down for you. I wanna make sure you guys understand what you're looking at. These are a focus on the prevalence of addiction. You can see all the different addictions, alcohol, tobacco, opioid use, and the number of people globally that are addicted. And you can see binge eating, internet, gaming disorder. That's a new one. Compulsive sexual behavior, gambling disorder. So there's a lot of substance and behavioral addictions. Their approach is the solution. Awaken is addressing addiction with new proprietary combined therapeutics, drugs and therapies that approach the treatment of addiction in a radically different way than before. What are we doing differently? Based on our new research, Awaken's drugs will target the brain's circuits that drive addiction through multiple receptors rather than single drug receptors. This circuits controls the behavioral drivers of addiction by focusing on circuit mechanisms rather than isolated receptors. Awaken's approach has the potential to be effective in the treatment of both substance and behavioral addictions. This disruption allows the individual to escape from the repetitive addiction behaviors and thoughts and in doing so engage with a psychotherapeutic process to enable lasting positive change. Medicine and therapy therapeutics. This is where Awaken's proprietary therapy comes in. Our therapy is working conjunction with our medicines enabling the patients to regain control over their lives and helping to learn new, more adaptive ways to respond to addictive urges, cravings and the underlying psychological processes that drive them. So you can see here to continue with the approach, the balanced brain state, no addiction, cognitive control, PFC controls the final decision making. The addicted brain excessive drives from memory and reward, pleasure circuits, depressed cognitive control and enhance the drive and salience functioning so the cognitive control no longer controls the behavior. So you guys can see the difference between a non-addicted brain and an addicted brain where Awaken treatments act to disrupt these addiction circuits to restore balance in the brain. So you can see here therapy, cognitive control, motivation drive and salience attribution and how the drugs work with reward prediction and pleasure, learning and memory. So the therapeutics development strategy our research team consists of world leading experts in the field of drug development, clinical research, psychiatry, psychotherapy and neurochemistry. So it's very important to understand that Awaken does what they do through a variety of psychedelics including ketamine, MDMA and new chemical entities otherwise known as NCEs, which you're gonna see here. Our team is building a pipeline of new therapeutic drugs and therapies to be used in combination. So we will focus our research activities on treating addictions where the consequences for the patient, their family and society are present, most severe with near medium and long-term programs. Near term utilizing ketamine, medium term utilizing MDMA and long-term using new chemical entities for substance and behavioral addictions. MDMA working with assisted psychotherapy for alcohol use disorder and ketamine near term working and assisted psychotherapy for substance and behavioral addictions. So different focuses for different disorders and different drugs and different solutions for different disorders and different behaviors. So this is the progress of this company. As you can see here, their pipeline, Awaken's pipeline and you can see here alcohol use disorder utilizing ketamine, MDMA and new chemical entities, gambling disorder utilizing ketamine and new chemical entities, binge eating disorder utilizing ketamine and new chemical entities, compulsive sexual behavior utilizing ketamine and new chemical entities, internet gaming disorder. They're actually helping people with this disorder now. This is very interesting. This is a new one that's obviously happening, ketamine and new chemical entities and substance addictions, new chemical entities. So there is a lot of different areas of focus here for Awaken. The company also operates two clinics. I wanna make sure everyone understands that this company is operating two clinics. One is in Norway through its acquisition of a company. And one in the UK, AWKN, Awaken aims to further expand its footprint in the UK and Europe by opening an additional six new clinics in 2022. So they have a lot of goals to grow. These guys have a lot of goals to grow in 2022. So be aware of that. That's a huge catalyst. Six new potential clinics could be opening in the UK and Europe in 2022 and expects to have a total of 20 clinics by the end of 2024. Awaken has also filed two provisional patents for two novel MDMA derived NCEs, Awaken 001 and Awaken 002. Furthering the company's intellectual property portfolio surrounding its research and developments for the treatment of addiction as well as a portfolio of an additional eight other provisional patents. So they're working on a lot, guys. These guys are working on a lot backed by the world's leading experts. This is Professor David Nutt, the chief research officer. So it's time to get it awakened and put Awaken on your watch list. Company further, once again, an additional eight. Wow, like furthering the company's intellectual property portfolio surrounding its research and developments for the treatment of addiction as well as a portfolio of an additional eight other provisional patents. Awaken's team is a real differentiator having some of the biggest names in the industry driving their work forward. Like Professor David Nutt, who we see here. You see here, Dr. Ben Sessa, the chief medical officer and Professor Celia Morgan, the head of ketamine assisted psychotherapy for addiction. So be aware of these people, these names that are really taking this sector and trying to make a difference. So why Awaken? Multiple scalable revenue streams, clinics from 2021, partnerships from 2022 and therapeutic commercialization from 2025, focus on addiction, substance and behavior, biggest unmet medical needs of our times. Current treatment options have limited efficacy and significant current and future market opportunity. Now I must remind you guys that psychedelics are in the early stages. These companies are very volatile. They are put them on your watches, put them on your radar, but do your due diligence. This is a sector that is still really early. A lot of these companies are awaiting FDA approval. So this is more of a long-term approach to investing. I do have positions in three psychedelic stocks. All of them are long-term positions. This is a new one that I'm learning about that I'm very interested in and I think you should be aware of. Put them on your radar, put them on your watch list. Awakenlifesciences.com is the website and their approach, a paradigm shift, targeting brain circuits rather than individual receptor sites, combined novel therapeutic drugs and therapies used in a combination. We've talked about that a lot with these guys. Potential to treat both substance and behavioral addictions. So that's what makes them completely game-changing. So they have an IP portfolio. You can see here 10 patent filings covering multiple chemical series and clinical targets, a completed phase two AB trial for ketamine, assisted psychotherapy to treat alcohol use disorder, AUD and a planned phase two B trial for MDMA as a treatment for AUD with ethics approval forecast for Q4 2021. Now, world-renowned team, we talked about Professor David Nutt, Professor Celia Morgan and Dr. Ben Sessa, Dr. Sean McNulty, Professor Barbara Mason and Dr. Harriet DeWitt. So a star-studded team and global research leaders in the field of psychedelic treatment for addiction. Dr. Ben Sessa led the world's only MDMA assisted psychotherapy and AUD study in BIMA and Professor Celia Morgan led the world's only ketamine assisted psychotherapy study, K-A-R-E. Prior to its initial listing, and we'll go back to the, you can see here the ketamine research program and the assets acquired, plant future activity, current activity and the market opportunity. Prior to its initial listing, Awaken Life Science has acquired the exclusive rights for the use and delivery of ketamine in the reduction of alcohol relapse, otherwise known as CARE, which I brought you guys here, CARE from Professor Celia Morgan. As you can see, and the focus was ketamine in the reduction of alcohol relapse, CARE psychotherapy intervention from the University of Exeter, UOE for treatment of alcohol use disorder, AUD, the CARE Clinic, this is their research program here as well, and assets acquired, current activity, plant future activity and the market opportunity. So you can see here the market opportunity is absolutely enormous. The CARE clinical trial, which began in 2016 and concluded in 2020 is the only phase to AB clinical trial to treat AUD using ketamine assisted psychotherapy and was led by Professor Celia Morgan, a leading ketamine expert who has since been appointed as AWK's head of ketamine assisted psychotherapy. So you can see a huge market opportunity, the NCE research program, assets acquired, current activity and plant future activity. So you can see here, they have a plan that goes all the way out till 2029. So this is a long-term approach when you're looking to investing. This is not a company that's going to have results overnight. All of these psychedelic companies that we've talked about are really early stage and there's been a lot of volatility. Some have done extremely well, like mind medicine. Others have been up and down. This is one that's done well. So you definitely need to put them on your radar, put them on your watch list. We believe that the upside is tremendous for the sector. Be selective, make sure you do your due diligence, do your research and invest in the best. The best is blessed. So make sure that when you're investing in anything that you're trying to buy the best in every single sector and awaken life sciences has an opportunity to be absolutely one of the best. Look at this growth potential in 2021, Europe and the United Kingdom. 2022 focusing once again on Europe and the United Kingdom. And in 2023, more focus on Europe with expansion to Belgium, Netherlands, France, Germany, Austria, Switzerland. So a lot of future growth and we're talking countries here. And this year focusing on Manchester, London, a second location, Birmingham, UK clinic number one, Nordics clinic times one and Dublin, Ireland. So lots of room for growth, lots of room for growth. You can see here the clinics our target is 20 clinics by the end of 2024. So really nice looking professional looking clinics, very clean, very sleek looking treatment program with the average of six treatment rooms per clinic treatment programs will cost between 6,000 and 7,500 euros each treatment program will consist of three to four ketamine sessions and eight therapy and integration sessions. Wow, that's going to be expensive. So they're going to have an opportunity to make a lot of money. We will deliver approximately eight patient treatment programs per treatment room per month. Each clinic will generate an average of four million in revenue per year. So guys team, the revenue potential is enormous. So they're focused on partnerships, purpose, focus and proposition. So obviously they're focusing on their target audience, their purpose and their proposition, licensing partnerships outside UK and Europe for awakens care methodology, proposition, access to IP and content, operating entity, certification, practitioner, practitioner certification, training, operating entity and practitioner, recertification, clinic operations advisory and awareness. This is awakened in the media. As you can see, they have been featured on Forbes, The Guardian, ABC News, The Times, The Daily Mail, The Daily Telegraph, Vice Benzinga, they've been featured in so many different places and now they're being featured on Rich TV Live. Very, very impressed with the capital structure. Like this is very important to us here at Rich TV Live. We love to understand the fundamentals and the capital structure and the market cap mean something to us. Look at the shares. Only 24,887,307 shares, that's bingo to me. 1.9 million options, 1.8 million warrants and fully diluted 28,645,092 shares. No debt, that's huge. And insider ownership of 23.82%. So very good amount of skin in the game. Escrowed security, 65.64%. So there is a lot of room for this stock to make moves. Progress versus competitor landscape. So you can see here the pre-clinical program, phase one, phase two A and phase two B and where they compare to some of the other companies in this sector like Mind Medicine which we brought you guys first and went up 1,000%. We've also talked about Saibin on our show. We've talked about Field Trip on our show. So you can see they're ahead of almost everyone with the exception of Maps which is in phase three and Compassion which is also in phase two B. Awaken is ahead of the pack. So definitely be aware of Awaken. Put them on your radar, put them on your watch list. They might be new to our community but the reality is these guys when you compare them to some of their peers they look extremely appetizing. As you could see here when you compare them to some of their peers and you can see where they are as far as their market cap, their market cap puts them right at the bottom with all of their peers. So why invest in Awaken? Multiple scalable revenue streams clinics from 2021 and partnerships from 2022, therapeutic commercialization from 2025. A revolutionary approach targeting brain circuits rather than individual receptor sites combined novel therapeutics, drugs and therapies used in combination potential to treat both substance and behavioral addictions. Team, we've talked about the team, their focus, addiction, substance and behavior one of the biggest unmet medical needs of our times current treatment options have limited efficacy and significant current and future market opportunity. IP portfolio, 10 patent filings covering multiple chemical series and clinical targets a completed phase two AB trial for ketamine assisted psychotherapy to treat AUD a planned phase two B trial for MDMA as a treatment for AUD and with ethics approval forecast for Q4 2021 and a global research leaders in the field of psychedelic treatments for addiction. Dr. Ben Sessa led the world's only MDMA assisted psychotherapy for AUD study in BIMA and professor Celia Morgan led the world's only ketamine assisted psychotherapy for AUD study care. These are some of the references if you guys would like to review some of the references and topics we talked about in the deck and if you have investor inquiries feel free to contact them directly for media inquiries that is awaken life sciences love to know what you guys think. If you liked the video, smash the like button comment down below, share the video everywhere and subscribe love to know what you guys think you can sign up for the newsletter in fact, I'm gonna sign up for the newsletter I wanna get to know everything that these guys are talking about and I just subscribed. So now I'm updated so anytime they have any new big breaking news I'll get access to it first. This is their website awaken life sciences. Thank you guys for watching. You're not winning, you're probably not watching we bring in the winners and we bring them to you first what do you think of awaken life sciences another psychedelic stock with revelation with revolutionary treatments for addictions and I think that they have enormous upside tight share structure and a model that's going to generate lots of revenue. So put them on your radar, put them on your watch list is your boy Rich from Rich TV Live and I'm out.